Research graph
References from Efficacy and safety of narlumosbart in combination with stereotactic body radiation therapy followed by first-line chemotherapy combined with immunotherapy in advanced driver gene-negative non-small cell lung cancer patients with bone metastases: a phase II, single-arm, single-centre clinical trial protocol. Local targets link to admitted publications; unresolved targets remain external evidence.
10.3322/caac.21590
10.3322/caac.21590 · External reference
10.3322/caac.21660
10.3322/caac.21660 · External reference
10.1634/theoncologist.5-6-463
10.1634/theoncologist.5-6-463 · External reference
Cancer Cell Colonisation in the Bone Microenvironment
10.3390/ijms17101674 · 2016 · External reference
Natural History of Non-Small-Cell Lung Cancer with Bone Metastases
10.1038/srep18670 · 2015 · External reference
10.1007/s11999-007-0051-0
10.1007/s11999-007-0051-0 · External reference
10.1016/j.cllc.2013.05.002
10.1016/j.cllc.2013.05.002 · External reference
The Therapeutic Effect and Clinical Outcome of Immune Checkpoint Inhibitors on Bone Metastasis in Advanced Non-Small-Cell Lung Cancer
10.3389/fonc.2022.871675 · 2022 · External reference
Novel predictors of immune checkpoint inhibitor response and prognosis in advanced non-small-cell lung cancer with bone metastasis
10.1002/cam4.5952 · 2023 · External reference
Bone Metastasis and Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer (NSCLC): Microenvironment and Possible Clinical Implications
10.3390/ijms23126832 · 2022 · External reference
10.1016/s1470-2045(18)30072-x
10.1016/s1470-2045(18)30072-x · External reference
10.1158/1078-0432.ccr-11-3310
10.1158/1078-0432.ccr-11-3310 · External reference
10.1016/j.ejca.2012.08.002
10.1016/j.ejca.2012.08.002 · External reference
10.1200/jco.2008.19.2146
10.1200/jco.2008.19.2146 · External reference
Efficacy and safety of JMT103 in patients with unresectable or surgically-challenging giant cell tumor of bone: a multicenter, phase Ib/II study
10.1038/s41467-024-53686-4 · 2024 · External reference
Safety, tolerability, and pharmacokinetics/pharmacodynamics of JMT103 in patients with bone metastases from solid tumors
10.3389/fonc.2022.971594 · 2022 · External reference
10.1016/j.ijrobp.2003.09.012
10.1016/j.ijrobp.2003.09.012 · External reference
10.1038/s41590-019-0561-4
10.1038/s41590-019-0561-4 · External reference
Pamiparib as consolidation treatment after concurrent chemoradiotherapy of limited-stage small cell lung cancer: a single-arm, open-label phase 2 trial
10.1186/s13014-024-02437-2 · 2024 · External reference
10.1158/1078-0432.ccr-14-1187
10.1158/1078-0432.ccr-14-1187 · External reference
10.1016/s0140-6736(15)01281-7
10.1016/s0140-6736(15)01281-7 · External reference
10.21873/anticanres.14933
10.21873/anticanres.14933 · External reference
Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: a randomized phase I/II trial
10.1136/jitc-2020-001001 · 2020 · External reference
Osteoblasts remotely supply lung tumors with cancer-promoting SiglecFhigh neutrophils
10.1126/science.aal5081 · 2017 · External reference
10.1016/j.tranon.2019.10.012
10.1016/j.tranon.2019.10.012 · External reference
The Contribution of the Immune System in Bone Metastasis Pathogenesis
10.3390/ijms20040999 · 2019 · External reference
10.1007/s00210-010-0596-4
10.1007/s00210-010-0596-4 · External reference
Combination therapy with immune checkpoint inhibitors and denosumab improves clinical outcomes in non-small cell lung cancer with bone metastases
10.1016/j.lungcan.2024.107858 · 2024 · External reference
10.1038/nrc.2018.6
10.1038/nrc.2018.6 · External reference
10.1016/j.it.2018.06.001
10.1016/j.it.2018.06.001 · External reference
10.1158/1078-0432.ccr-20-1790
10.1158/1078-0432.ccr-20-1790 · External reference
Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non-Small Cell Lung Cancer: Results of the PEMBRO-RT Phase 2 Randomized Clinical Trial
10.1001/jamaoncol.2019.1478 · 2019 · External reference
